Whitney Hall, APRN
Family · Post Falls, IDNPI 1679012728
Payments from drug & device makers
Across 106 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$225
- GSK$223
- AbbVie$180
- Astellas Pharma US Inc$175
- Amgen$165
- Novo Nordisk$131
- plus $584 from 18 others
What the payments were for
- Food & beverage$1,682100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $225 |
| GSK | 17 | $223 |
| AbbVie | 10 | $180 |
| Astellas Pharma US Inc | 16 | $175 |
| Amgen(2 entities) | 9 | $165 |
| Novo Nordisk | 8 | $131 |
| Exact Sciences | 5 | $110 |
| Pfizer | 5 | $81 |
| Corcept Therapeutics | 3 | $69 |
| Lilly USA, LLC | 3 | $53 |
| Merck | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Boston Scientific | 1 | $27 |
| Dexcom, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Organon | 3 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Exeltis, USA Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Axonics, Inc. | 1 | $13 |
How this compares
$1,682 in reported general payments places this provider in the 80th percentile of 809 family providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 38 | $45,530 |
| JardianceEmpagliflozin | 34 | $43,983 |
| EliquisApixaban | 48 | $38,913 |
| MounjaroTirzepatide | 29 | $38,079 |
| FarxigaDapagliflozin Propanediol | 25 | $23,933 |
| JanuviaSitagliptin Phosphate | 12 | $9,289 |
| VeozahFezolinetant | 12 | $6,323 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,044 |
| Levothyroxine Sodium | 248 | $2,855 |
| Atorvastatin Calcium | 169 | $2,300 |
| BreynaBudesonide/Formoterol Fumarate | 20 | $2,032 |
| Lurasidone Hcl | 12 | $2,019 |
| Gabapentin | 80 | $1,982 |
| Losartan Potassium | 162 | $1,935 |
| Liothyronine Sodium | 36 | $1,738 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $131 | $45,53038 claims |
| Boehringer IngelheimJardiance | $17 | $43,98334 claims |
| PfizerEliquis | $81 | $38,91348 claims |
| Lilly USA, LLCMounjaro | $53 | $38,07929 claims |
| AstraZenecaFarxiga | $225 | $23,93325 claims |
| MerckJanuvia | $35 | $9,28912 claims |
| Astellas Pharma US IncVeozah | $175 | $6,32312 claims |
| GSKBreo Ellipta | $223 | $5,04413 claims |
| AbbVieArmour Thyroid, Synthroid | $180 | $3,09232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 809 family providers in Idaho.
Other family in Post Falls
- Nancy HunterPost Falls$4K
- Bobbi BullockNampa$609K
- Michael ParkerMeridian$69K
- Jessica BraksiekBoise$41K
- Travis BlaserBoise$33K
- Alysha SchlackNampa$23K
- Jennifer WatsonCoeur D Alene$21K
- Amber MasseIdaho Falls$17K
- Brian KittelsonMeridian$16K
- Devon MoserBoise$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.